Baxter Q1 revenue rises 3%, beats analyst expectations

Overview

• Global medtech firm's Q1 revenue rose 3%, beating analyst expectations

• Adjusted diluted EPS for Q1 was $0.37, beating analyst expectations

• Organic revenue fell 1% due to lower U.S. sales and segment headwinds

Outlook

• Baxter sees 2026 reported sales growth from continuing operations flat to 1%

• Company expects 2026 organic sales growth from continuing operations to be approximately flat

• Baxter forecasts 2026 adjusted EPS from continuing operations of $1.85 to $2.05

Result Drivers

• INFUSION THERAPIES & TECHNOLOGIES - Lower infusion pump sales, impacted by shipment and installation hold of Novum IQ LVP and tough prior-year comparison, weighed on segment results

• FRONT LINE CARE - Lower sales in Front Line Care due to timing of orders and planned global portfolio exits

• HIGHER COSTS - Adjusted EPS decline reflected higher costs related to tariffs and manufacturing, including lower absorption

Company press release: ID:nBw5xRmMLa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 15 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Baxter International Inc is $20.00, about 18.3% above its April 29 closing price of $16.90

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.